Ionis offers a high-risk commercial transformation: strong wholly owned launch momentum and pivotal 2026 catalysts offset persistent losses, clinical setbacks, pricing pressure, and limited base-case five-year upside.
Overview
Ionis Pharmaceuticals is transforming from a partner-dependent RNA discovery company into an integrated commercial biopharmaceutical company. Its revenue mix now combines product sales from wholly owned launches, recurring royalties such as SPINRAZA, and collaboration revenue, with U.S. commercialization increasingly handled internally and international markets served by partners. **The near-term commercial proof point is the ramp of DAWNZERA and TRYNGOLZA**: Q2 2026 commercial revenue increased 15% to $118.6 million, DAWNZERA sales were $26.0 million, up 63% sequentially, and TRYNGOLZA sales were $5.0 million after a strategic 60% WAC reduction intended to improve payer access. Total Q2 revenue of $267.9 million fell year over year only because the prior-year period included a $280 million Ono upfront payment; excluding that item, revenue grew 56%. Ionis reaffirmed FY2026 revenue guidance of $875–$900 million, including $110–$120 million of DAWNZERA sales and $100–$110 million of TRYNGOLZA sales, while still expecting a $425–$475 million non-GAAP operating loss. **The key valuation debate is whether launch operating leverage and 2026 catalysts can deliver 2028 cash-flow breakeven.** Zilganersen, bepirovirsen, and pelacarsen provide major upside, but eplontersen’s ATTR-CM failure and persistent losses keep risk high. At approximately $60, the five-year base case reaches only $61.24, while the high case reaches $164.52.